



UNICHEM
LABORATORIES LTD.

March 27, 2019

Department of Corporate Services

Bombay Stock Exchange,
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Mr. Hari K.

Asst. Vice President - Operations
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051.

Ref: BSE Scrip Code - 506690 : NSE Symbol - UNICHEMLAB

Dear Sir,

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of Final ANDA Approval from USFDA for Unichem's Tadalafil Tablets 2.5 mg, 5 mg, 10 mg and 20 mg.

For **Unichem Laboratories Limited**

Sandip Ghume

Deputy CFO



**UNICHEM
LABORATORIES LTD.**

Mumbai, Wednesday, March 27, 2019

PRESS RELEASE

Unichem Laboratories Limited is pleased to announce that it has received final Approval for its ANDA, Tadalafil Tablets, 2.5 mg, 5 mg 10 mg and 20 mg from the United States Food and Drug Administration (USFDA) for a generic version of ELI LILLY's Cialis®, 2.5 mg, 5 mg, 10 mg and 20 mg.

Unichem's Tadalafil Tablets are indicated for the treatment of :

- erectile dysfunction (ED).
- the signs and symptoms of benign prostatic hyperplasia (BPH).
- ED and the signs and symptoms of BPH (ED/BPH).

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms. More information about the Company can be found at www.unichemlabs.com

For more information please contact:

Ms. Neema Thakore

Ph: +91-22-66888 404

E-mail: neema.thakore@unichemlabs.com

Disclaimer:

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.